//June 14, 2011
BETHESDA — Cancer drug developer Micromet Inc. on Tuesday named Ulrich Grau, a biopharmaceutical industry veteran, as its executive vice president and chief operating officer, effective immediately.
Grau has more than 30 years of experience in operations and research and development at biotechnology and pharmaceutical companies.
Grau most recently served as president and CEO of Lux Biosciences Inc., a clinical stage private ophthalmic company that he co-founded.
Previously, he worked at such companies as BASF Pharma/Knoll, Aventis Pharma and Hoechst Marion Roussel.
Micromet’s lead product candidate is the potential cancer treatment blinatumomab.
Shares of Micromet rose 2 cents to $5.48 in late morning trading.
Sign up for your daily digest of Maryland News.
Erie Insurance sues Maryland Insurance Administration over finding of race discr[...]
9/6/2023
Moore appoints members to authority for sustaining thoroughbred horse racing
9/6/2023
Md. Bar Foundation presents awards, announces class of fellows
9/6/2023
Md. Board of Elections names successor to longtime administrator Lamone
8/6/2023
At MSBA, one panel asks whether non-lawyers can help improve access to justice
8/6/2023
Donald Trump described Pentagon plan of attack and shared classified map, indict[...]
9/6/2023
Trump indicted: What to know about the documents case and what’s next
9/6/2023
Lawyers blame ChatGPT for tricking them into citing bogus case law
9/6/2023
Supreme Court voting rights ruling stuns minority voters, who hope it expands th[...]
9/6/2023
Trump indicted in classified documents case in a historic first for a former pre[...]
8/6/2023
Submit an entry for the business calendar